Who
Denis R. Burger
Other role
Company insider
Files Form 4 as: Director and Other, Aptose Biosciences; Director, CytoDyn; Executive Chairman, Biocurex; Chief Executive Officer, Sarepta Therapeutics.
In numbers
- Trades disclosed
- 80
- Buys
- 3
- Sells
- 0
- Bought
- $65K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 16 Feb 2006
- Last trade
- 30 Jun 2026
- Last filed
- 1 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 1 Jul 2026 | Aptose BiosciencesBiotechnology | SEC FORM 4 Code D | $12070 at $1.72 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —60,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —3,333 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —100,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —3,333 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —100,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —160,334 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —40,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —5,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —60,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —10,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —160,334 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —40,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.